Trusted Resource for Clinical Trials, Protocols & Progress
Most rare diseases affect a small number of individuals—typically fewer than 200,000 in the U.S., and often less than 1 in 2,000 in the EU. When ultra-rare diseases are involved, patient populations may fall below 100 worldwide. Relying on a single country or region for recruitment is insufficient and often leads to under-enrolled studies and regulatory delays.
Click to read the full article.
In the realm of rare disease clinical research, patient advocacy groups are more than just support networks—they are powerful allies in trial recruitment. These organizations have deep-rooted relationships with patient communities, possess condition-specific knowledge, and operate with the trust that researchers and sponsors often lack at the outset.
Click to read the full article.
Informed consent is a cornerstone of ethical clinical research, ensuring participants understand the risks, benefits, and procedures before enrolling in a trial. In the context of rare and orphan diseases, the consent process becomes even more critical—and complex. Patients are often children, cognitively impaired, or part of a tight-knit caregiver dynamic. Additionally, the scarcity of disease-specific information can lead to therapeutic misconception—where patients believe enrollment guarantees benefit.
Click to read the full article.
Telemedicine has become a pivotal tool in expanding access to clinical trials—particularly for patients with rare diseases who often reside far from major research centers. These patients face unique barriers to trial participation, including travel burden, mobility limitations, and limited local expertise. Telemedicine enables decentralized trial models that bring studies directly to the patient’s home.
Click to read the full article.
Social media has become a powerful tool for healthcare communication, especially in the rare disease space where traditional recruitment strategies fall short. Given the scarcity of eligible participants and their global dispersion, reaching patients through digital channels offers unique advantages in trial awareness, education, and enrollment.
Click to read the full article.
Recruiting pediatric patients for rare disease trials is among the most complex tasks in clinical research. The small population size, strict eligibility criteria, and logistical and ethical considerations make it difficult to meet enrollment targets. When the condition is ultra-rare and affects children, the challenges multiply—requiring innovative, patient-centric approaches that prioritize caregivers, regulatory compliance, and feasibility.
Click to read the full article.
In the rare disease space, lack of awareness remains a significant barrier to patient participation in clinical trials. Many patients are unaware that trials exist for their condition, and even fewer understand the role they can play in advancing new treatments. Unlike common diseases, rare conditions often lack dedicated healthcare pathways, making targeted outreach essential for successful recruitment.
Click to read the full article.
Orphan Drug Designation (ODD) is a regulatory incentive program established to encourage the development of treatments for rare diseases, which often lack commercial appeal due to small patient populations. In the U.S., the Orphan Drug Act of 1983 laid the foundation for this initiative, followed by similar frameworks in the EU (Regulation (EC) No 141/2000) and other regions.
Click to read the full article.
Rare Disease Day, observed annually on the last day of February, is a globally recognized event aimed at raising awareness for the 300+ million people living with rare diseases worldwide. Since its inception in 2008, it has grown into a powerful movement supported by patients, caregivers, healthcare providers, industry, and researchers across more than 100 countries.
Click to read the full article.
Rare diseases—often debilitating, progressive, and life-threatening—affect millions worldwide, yet most lack approved treatments. Traditional drug development timelines spanning 10–15 years are incompatible with the urgent needs of rare disease patients. Recognizing this, regulatory agencies like the U.S. Food and Drug Administration (FDA) have developed expedited pathways to speed up access to safe and effective therapies for serious and life-threatening conditions with unmet medical need.
Click to read the full article.
